Death cross is a high-conviction structural breakdown signal, not an accumulation zone. ATR compression during downtrend means the move is becoming more orderly before the next leg, not that sellers are exhausted.

• 50 SMA crossed below 200 SMA at $554.37 vs. $554.71
• Price is $32 below all three major moving averages simultaneously
• 10 EMA declining roughly $1.30 per day
• Bollinger midline rolled from $584.88 (Aug 20) to $538.72 (Sep 22) — a $46 drop in a month
• First real capitulation will come on decisive close below $512

↩ rebuts: “Death cross as accumulation zone for fundamentally exceptional names”

MACD at -0.26 means the bearish crossover is mature but momentum has NOT begun to reverse — this is early innings, not exhaustion. Capitulation would show histogram readings of -3 to -5 with positive divergence.

• MACD histogram at -0.26 — barely off zero line, not exhaustion
• MACD swung from +19.02 (Aug 14 peak) to -8.42 — a -27 point collapse in momentum in just 27 sessions
• Price has broken key structural levels: 50 SMA and 200 SMA

↩ rebuts: “Bull claim that MACD signals are bullish”

RSI at 38.32 is a textbook continuation pattern, not an entry signal. RSI has not printed oversold (<30), meaning sellers haven't capitulated. RSI needs to close back above 50 on higher highs to signal a bottom.

• RSI at 38.32 and falling
• RSI has broken below 40 but has NOT printed oversold (<30)
• No bullish divergence
• RSI trending down with no bullish divergence

↩ rebuts: “Bull claim that RSI at 38.32 is an entry signal”

Forward EPS estimate of $7.94 relies on peak quarter run-rate sustainability that's historically optimistic. The four-quarter trailing average of $6.66 suggests more sober estimates.

• Q3 2025 EPS: $6.95
• Q4 2025 EPS: $5.80
• Q1 2026 EPS: $6.44
• Q2 2026 EPS: $7.94
• Q2 2026 is about 19% above four-quarter trailing average of $6.66
• TTM figure of $27.14 vs. forward consensus using peak quarter run-rate annualized
• Sell-side analysts have systematic upward bias on defense names due to banking relationships

↩ rebuts: “Bull claim that Q2 2026 EPS of $7.94 proves accelerating earnings power”

Negative tangible book and 234% D/E is not a red herring — it's a systemic risk that investors are ignoring. Deferred revenue is a liability requiring delivery, not a cash buffer. If LMT takes a $5B write-down, equity holders get wiped first behind $20.54B of debt.

• $20.54B total debt
• $12.15B current deferred revenue as a liability requiring delivery
• A-/A2 credit ratings assume government appropriation stability and program execution
• With 96% no-cut Fed and fiscal pressure, ratings may not reflect stress scenario

↩ rebuts: “Bull claim that negative tangible book and high D/E are red herrings”

Stealth drone pushback signals capital allocation risk, lost franchise potential, and technology drift. LMT's 'build before they buy' culture worked in expanding DoD budgets but is a risk in CR-driven budget uncertainty. Today's autonomous systems landscape is crowded and skeptical of legacy prime integration.

• Air Force pushback on LMT's stealth drone
• F-35 program history of build-on-spec
• Defense procurement shifting toward iterative software integration
• LMT capital allocation anchored in 1990s-era industrial thinking

↩ rebuts: “Bull claim that stealth drone news is immaterial”

Hawkish Fed is a headwind, not a tailwind. Higher discount rates compress present value of LMT's $32.75 forward EPS trajectory. Rising government debt service costs increase pressure on defense budgets. The 15.95x forward P/E is only attractive if forward EPS materializes under lower discount rates.

• LMT beta of 0.10 calculated against broad equity returns — separate from interest rate sensitivity
• Forward EPS trajectory: $32.75
• 15.95x forward P/E on current price
• High rates make DoD appropriations a political target

↩ rebuts: “Bull claim that low beta makes LMT a bond with optionality benefiting from hawkish Fed”

Anduril valuation race validates narrative shift away from legacy primes toward software-defined defense. Valuation rerating starts with narrative — if Anduril captures next-gen defense narrative, LMT gets compressed to industrial multiples (10-12x P/E) regardless of forward EPS growth.

• Polymarket volume on Anduril-LMT comparison: $9.5K
• Defense procurement shifting toward iterative software integration
• LMT capital allocation anchored in 1990s industrial thinking
• Legacy primes losing narrative race to software-defined competitors

↩ rebuts: “Bull claim that Anduril valuation is irrelevant due to small volume”

Sentiment data shows institutional distribution in progress, not a mixed picture. The selloff predates current headlines, confirming structural rather than headline-driven selling.

• 30-day return: -5.0%
• Tuesday close: -2.44% to $522.34
• Defense sector down ~3% on Hormuz reopening
• Reddit silence = no retail bid to absorb institutional selling
• 24/7 Wall St noted: 'the selloff started long before today's headline'
• Bullish news flow being rejected, not absorbed by the market

↩ rebuts: “Bull claim that sentiment is 'mixed' at 5.6/10”

The probability-weighted path is asymmetric to the downside. First target of $540 requires 3.4% move into the death-cross resistance zone at $554-555. Death cross historically requires a meaningful fundamental catalyst to fail — none visible on horizon.

• Entry: $522
• Stop: $510 (12 points below entry)
• First target: $540 = 18 points upside (into death-cross resistance)
• Second target: $555 = 33 points upside (requires reclaiming 50/200 SMA cluster)
• Third target: $565 = 43 points upside
• Downside target $512: 2% downside with ~55% probability
• Downside target $500: 4.3% downside
• Downside target $490: 6.2% downside
• 55% probability of continuation toward $500-$490 vs. 35% probability of bounce

↩ rebuts: “Bull claim of 3.3-to-1 risk/reward with $10 stop and $33 upside target”